Open Targets is a pioneering brand that strives to revolutionize drug discovery by utilizing human genetics and genomics data. As a public-private partnership, Open Targets generates evidence on the validity of therapeutic targets through genome-scale experiments and analysis. Their commitment to innovation is evident in their use of experimental and informatics approaches to develop safe and effective drugs.

They offer two primary platforms: the Open Targets Platform and Open Targets Genetics. The Open Targets Platform is a comprehensive and open-source tool that aggregates public data sources. It assists scientists in identifying and prioritizing potential therapeutic drug targets for further investigation.

On the other hand, Open Targets Genetics is a variant-centric statistical evidence tool. It allows for the prioritization of candidate causal variants and the identification of potential drug targets. Open Targets also conducts large-scale systematic experimental projects and publishes research publications.

Their latest papers highlight target identification approaches in the fields of oncology, neurodegeneration, and immunity and inflammation. By integrating data, innovation, and collaboration, Open Targets aims to transform the process of drug discovery and improve patient outcomes